InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.084 0.006 (6.67%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 NOX Releases Initial Newsletter for Nyrada Subsidiary 2 Aug 2019 12:25PM $0.460 $0.084 fallen by 81.74%
$26 Appendix 4C - Quarterly 29 Jul 2019 8:59AM $0.480 $0.084 fallen by 82.50%
$26 Appendix 3B 25 Jul 2019 1:31PM $0.485 $0.084 fallen by 82.68%
$26 Section 708 Certificate 25 Jul 2019 1:31PM $0.485 $0.084 fallen by 82.68%
$26 Appendix 3B 23 Jul 2019 12:44PM $0.450 $0.084 fallen by 81.33%
$26 Section 708 Certificate 23 Jul 2019 12:42PM $0.450 $0.084 fallen by 81.33%
$26 Initial Director's Interest Notice 19 Jul 2019 4:05PM $0.490 $0.084 fallen by 82.86%
$26 Final Director's Interest Notice 19 Jul 2019 4:03PM $0.490 $0.084 fallen by 82.86%
$26 NOX Announces AU$26 Million Funding Facility 19 Jul 2019 9:51AM $0.455 $0.084 fallen by 81.54%
$26 NOX Releases Latest Newsletter 17 Jul 2019 10:38AM $0.425 $0.084 fallen by 80.24%
$26 Board Changes Ahead of Corporate Growth 16 Jul 2019 9:51AM $0.450 $0.084 fallen by 81.33%
$26 SNMMI 2019 Conference LuPIN Presentation Released 2 Jul 2019 9:59AM $0.460 $0.084 fallen by 81.74%
$26 Conference Hears of Positive Interim Data from LuPIN Trial 26 Jun 2019 9:25AM $0.500 $0.084 fallen by 83.20%
$26 NOX Subsidiary, Nyrada Inc, Receives R&D Rebate 7 Jun 2019 10:43AM $0.545 $0.084 fallen by 84.59%
$26 Noxopharm Corporate Presentation June 2019 6 Jun 2019 9:14AM $0.575 $0.084 fallen by 85.39%
$26 DARRT-1 Study Fully Enrolled 30 May 2019 8:41AM $0.625 $0.084 fallen by 86.56%
$26 Promising Data Leads to Expansion of LuPIN Trial 23 May 2019 8:33AM $0.590 $0.084 fallen by 85.76%
$26 LuPIN Trial Demonstrates High Rates of Response 20 May 2019 10:27AM $0.550 $0.084 fallen by 84.73%
$26 Change of Director's Interest Notice - GK 8 May 2019 9:23AM $0.595 $0.084 fallen by 85.88%
$26 Appendix 3B 8 May 2019 9:18AM $0.595 $0.084 fallen by 85.88%
$26 DARRT Treatment Has Lasting Disease Control at Six Months 2 May 2019 9:35AM $0.650 $0.084 fallen by 87.08%
$26 Veyonda and Immuno-Oncology Effect Explained 29 Apr 2019 9:21AM $0.495 $0.084 fallen by 83.03%
$26 Appendix 4C - Quarterly 26 Apr 2019 9:01AM $0.460 $0.084 fallen by 81.74%
$26 Change in Noxopharm Limited Board Structure 23 Apr 2019 8:49AM $0.480 $0.084 fallen by 82.50%
$26 Idronoxil Confirmed as New Immuno-Oncology Drug 16 Apr 2019 9:54AM $0.375 $0.084 fallen by 77.60%

526 - 550 of 796 results

Page 22 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.